Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad, Prof. C.R. Rao Road, Hyderabad 500046, India.
Curr Protein Pept Sci. 2022;23(4):271-289. doi: 10.2174/1389203723666220519155025.
Human parasites cause several diseased conditions with high morbidity and mortality in a large section of the population residing in various geographical areas. Nearly three billion people suffer from either one or many parasitic infections globally, with almost one million deaths annually. In spite of extensive research and advancement in the medical field, no effective vaccine is available against prominent human parasitic diseases that necessitate identification of novel targets for designing specific inhibitors. Vitamin B6 is an important ubiquitous co-enzyme that participates in several biological processes and plays an important role in scavenging ROS (reactive oxygen species) along with providing resistance to oxidative stress. Moreover, the absence of the de novo vitamin B6 biosynthetic pathway in human parasites makes this pathway indispensable for the survival of these pathogens. Pyridoxal kinase (PdxK) is a crucial enzyme for vitamin B6 salvage pathway and participates in the process of vitamers B6 phosphorylation. Since the parasites are dependent on pyridoxal kinase for their survival and infectivity to the respective hosts, it is considered a promising candidate for drug discovery. The detailed structural analysis of PdxK from disease-causing parasites has provided insights into the catalytic mechanism of this enzyme as well as significant differences from their human counterpart. Simultaneously, structure-based studies have identified small lead molecules that can be exploited for drug discovery against protozoan parasites. The present review provides structural and functional highlights of pyridoxal kinase for its implication in developing novel and potent therapeutics to combat fatal parasitic diseases.
人类寄生虫在居住在不同地理区域的大部分人群中引起多种高发病率和高死亡率的疾病。全球近 30 亿人患有一种或多种寄生虫感染,每年有近 100 万人死亡。尽管在医学领域进行了广泛的研究和进展,但针对一些主要的人类寄生虫病仍没有有效的疫苗,这些疾病需要确定新的靶标来设计特定的抑制剂。维生素 B6 是一种重要的普遍存在的辅酶,参与多种生物过程,在清除 ROS(活性氧)以及提供抗氧化应激方面发挥着重要作用。此外,人类寄生虫中缺乏从头合成维生素 B6 的途径,使得这条途径对于这些病原体的生存是必不可少的。吡哆醛激酶(PdxK)是维生素 B6 回收途径的关键酶,参与维生素 B6 磷酸化的过程。由于寄生虫依赖吡哆醛激酶来生存和感染各自的宿主,因此它被认为是药物发现的有前途的候选物。来自致病寄生虫的 PdxK 的详细结构分析为该酶的催化机制以及与人类对应物的显著差异提供了深入的了解。同时,基于结构的研究已经确定了可以用于针对原生动物寄生虫的药物发现的小分子先导化合物。本综述提供了吡哆醛激酶的结构和功能要点,为开发新型有效的治疗方法以对抗致命的寄生虫病提供了依据。